Consultant Nephrologist & Transplant Physician

Dr Christopher
Lawrence

HKC Kidney & Transplant

Specialist care for all aspects of kidney disease, from early-stage CKD to complex transplant management — including access to the most advanced molecular diagnostics available.

Dr Christopher Lawrence
About

Dr Christopher Lawrence

I am a consultant general physician and nephrologist specialising in the treatment of patients with medical kidney problems. I see patients from all over the UK with a wide spectrum of disorders — from abnormalities in urine or blood tests to complex multi-system illnesses such as vasculitis.

I treat patients with all stages of chronic kidney disease, acute kidney injury, and kidney transplants. General medical conditions I treat include hypertension, gout, and obesity.

I studied medicine at St Mary's Hospital Medical School (now part of Imperial College, London), qualifying in 2001. I subsequently trained at St Mary's Hospital, The Royal Brompton Hospital and Chelsea & Westminster Hospital before joining the North Thames Nephrology specialist registrar rotation.

I undertook research in transplant immunology at Imperial College (Hammersmith Hospital) and was awarded a Doctorate in Immunology in 2014. During training I also gained a Master's degree in Law. I was appointed Consultant Nephrologist with a specialist interest in transplantation in East & North Hertfordshire in 2012, and in 2016 was appointed Honorary Consultant Nephrologist at Addenbrooke's Hospital, Cambridge.

In 2020 I left NHS work to focus on private practice and on advancing non-invasive diagnostic testing in kidney disease — work that now encompasses molecular diagnostics, digital health, and patient education.

In addition to clinical work I co-supervised a PhD student at the University of Hertfordshire and have presented research at national and international conferences including the American Society of Nephrology and the American Transplant Congress.

Qualifications

  • FRCP (UK) 2017 — Royal College of Physicians
  • MD (Res) 2014 — Imperial College London
  • Diploma UEMS (Kidney & Pancreas Transplantation) 2011 — European Union of Medical Specialists
  • MRCP (Nephrology) 2009 — Royal College of Physicians
  • LLM 2009 — De Montfort Law School
  • MRCP (UK) 2004 — Royal College of Physicians
  • MBBS 2001 — Imperial College London
  • BSc (Hons) 1998 — Imperial College London

Professional Membership

  • UK Kidney Association
  • The British Transplantation Society
  • Royal College of Physicians of London

Secretary

  • Elaine Coles
  • 07375 064324
  • info@hertskidneycare.co.uk
Advanced Transplant Diagnostics

Cutting-edge care
for transplant patients

Kidney transplantation is one of medicine's most demanding specialisms. Managing a transplanted kidney requires vigilance, experience, and increasingly — access to the very latest diagnostic technologies. Dr Lawrence combines decades of transplant experience with molecular tools that were unavailable to most patients only a few years ago.

Non-invasive

Cell-free DNA (cfDNA)

When a transplanted kidney is under immunological attack, it sheds tiny fragments of donor DNA into the bloodstream. Measuring this donor-derived cell-free DNA — from a simple blood test — provides an early, accurate signal of rejection or injury, often before conventional markers change.

This approach is transforming transplant monitoring: it can detect subclinical rejection earlier, guide immunosuppression decisions, and reduce unnecessary biopsies — all from a blood draw rather than an invasive procedure.

Earlier detection means earlier intervention — protecting more of your kidney function for longer.
Molecular Microscopy

MMDx — Molecular Microscope

When a biopsy is needed, the Molecular Microscope Diagnostic System (MMDx) goes far beyond conventional histology. Developed by the Halloran group in Edmonton, it analyses gene expression across thousands of genes in the biopsy tissue, producing a precise molecular diagnosis of what is happening in the kidney at a cellular level.

MMDx can distinguish T-cell mediated rejection, antibody-mediated rejection, borderline injury, and other conditions with a precision conventional microscopy alone cannot match — leading to more targeted treatment decisions.

The same biopsy specimen; an entirely new dimension of diagnostic information.
Discuss your transplant care Find a clinic
What I Treat

Clinical Services

A full-spectrum nephrology service, from early detection to complex disease management.

Kidney Conditions

Chronic kidney disease (all stages)
Acute kidney injury
Kidney transplantation
Glomerulonephritis
Diabetic nephropathy
Hypertensive nephropathy
Polycystic kidney disease
Kidney stones
Lupus nephritis
Vasculitis
Nephrotic syndrome
Renovascular disease
Proteinuria & haematuria
Urinary tract infections

General Medicine & Procedures

Hypertension
Gout
Obesity
Kidney biopsies
Line insertions
DVLA medicals
Report writing
Digital Health

Tools & Resources

Free tools to help you understand and manage your kidney health.

🫘

Kidney Checker

Calculate your eGFR, check your CKD stage, assess your 5-year kidney failure risk, and track trends over time. Built on KDIGO 2024 and NICE NG203 guidelines.

Open Kidney Checker
📱

Patient Thread App

A secure, private space to log symptoms, track medications, store test results, and share a curated health summary with your clinical team — between appointments.

Learn More
🛒

Kidney Health Kit

Dr Lawrence's personally selected monitoring equipment — blood pressure monitors, urine test strips, and body composition scales — available on Amazon.

View the Store
Patient Information

Understanding Your Kidneys

Clear explanations of the conditions, tests, and treatments you are most likely to encounter as a kidney patient.

eGFR stands for estimated Glomerular Filtration Rate — it is a measure of how well your kidneys are filtering waste from the blood. It is calculated from a simple blood test (serum creatinine) alongside your age and sex.

A normal eGFR is above 90 mL/min/1.73m². Chronic Kidney Disease (CKD) is classified into stages based on how low this number has fallen:

  • Stage 1: eGFR ≥ 90 — kidney damage present but function near normal
  • Stage 2: eGFR 60–89 — mildly reduced
  • Stage 3a: eGFR 45–59 — mildly to moderately reduced
  • Stage 3b: eGFR 30–44 — moderately to severely reduced
  • Stage 4: eGFR 15–29 — severely reduced
  • Stage 5: eGFR < 15 — kidney failure

The stage alone does not tell the whole story. The trend over time and the level of protein in your urine (albumin-to-creatinine ratio, or ACR) are equally important in understanding your risk and guiding your care.

Healthy kidneys filter the blood but keep protein inside the body. When protein appears in the urine — called proteinuria — it suggests the kidney's filter is not working as it should.

The most important protein to measure is albumin, measured as the albumin-to-creatinine ratio (ACR) in a urine sample. A raised ACR — called albuminuria — is an independent marker of kidney risk and cardiovascular risk, even at very low levels.

Causes include diabetes, high blood pressure, glomerulonephritis (inflammation of the kidney filter), and many other conditions. The cause matters — and finding it early opens the door to treatment that can significantly slow progression.

A kidney transplant replaces the function of failed kidneys with a donor organ, placed in the lower abdomen (the original kidneys are usually left in place). Transplanted kidneys can function for many years — but require careful, lifelong monitoring and immunosuppression (medication to prevent rejection).

Monitoring typically involves regular blood tests (creatinine, tacrolimus levels), urine protein measurements, blood pressure checks, and periodic ultrasound scans. When problems are detected, a biopsy may be needed to identify the cause precisely.

Dr Lawrence also offers access to advanced molecular monitoring — see the Advanced Transplant Diagnostics section for more information on cfDNA and MMDx.

The relationship between hypertension and kidney disease runs in both directions. High blood pressure is one of the most common causes of CKD; and CKD itself raises blood pressure as the kidneys' ability to regulate salt and fluid balance deteriorates. This creates a cycle that requires careful management.

Blood pressure targets are lower in kidney disease than in the general population — particularly when proteinuria is present. Medications called ACE inhibitors or ARBs are often preferred because they both lower blood pressure and reduce protein leak, offering dual kidney protection.

A first appointment typically lasts 45–60 minutes. Dr Lawrence will want to review your full medical history, any previous blood and urine tests, imaging, and medications. It is helpful to bring:

  • A list of all current medications and doses
  • Any recent blood test results or letters from your GP
  • Any imaging reports (ultrasound, CT, MRI)
  • A urine sample if possible (first morning urine is ideal)

The consultation will usually conclude with a clear explanation of the findings, a formulated diagnosis or differential, and a management plan — including any additional tests needed. Dr Lawrence aims to ensure you leave with a clear understanding of your condition and next steps.

Dietary recommendations in kidney disease depend on the stage and cause, but some general principles apply widely:

  • Salt: Limiting salt intake helps blood pressure control and reduces fluid retention — aim for under 6g per day
  • Protein: Moderating protein intake (not eliminating it) may reduce the burden on damaged kidneys in later-stage CKD
  • Potassium: When kidneys fail to excrete potassium normally, high-potassium foods (bananas, potatoes, tomatoes) may need to be limited
  • Phosphate: Late-stage CKD often requires restriction of phosphate-rich foods (dairy, processed meats, fizzy drinks)

Dietary advice should always be personalised — what applies to one patient may not apply to another. A renal dietitian referral is often part of CKD management.

A 24-hour urine collection measures how much of a substance (such as protein, creatinine, calcium, or uric acid) your kidneys produce over a full day. To get an accurate result, every drop of urine during that period must be collected.

Before you start — collect the right bottles

Collect your bottles from the hospital pathology department before the day of collection. Different tests require different bottles:

  • Plain bottles — for creatinine clearance, protein, urate, and urine osmolality
  • Strong acid containers (marked with a hazard label) — for calcium, phosphate, oxalate, and metanephrins. Handle with care; splashes can cause skin burns.

If there is any chance you might produce more than 2.5 litres, take a second bottle. It is better to return an unused bottle than to have to repeat the entire collection.

You will also need a clean 1-litre plastic jug to use as an intermediate receptacle. Do not pass urine directly into the collection bottle. Discard the jug after the collection is complete.

Step-by-step instructions

  1. Choose a convenient day when you can collect every void and return the sample the following morning.
  2. On waking, pass urine as normal and discard this first sample. Note the time — this is the start of your 24-hour period.
  3. From this point, collect every urine void into your jug and transfer to the collection bottle.
  4. The following morning, collect the first void of the day. Note the time — this is the end of the 24-hour period. Include this sample in the collection.
  5. Keep the bottles at room temperature throughout. If collecting for protein or metanephrins, keep them refrigerated.
  6. If you miss a void, discard the entire collection and start again on another day. An incomplete collection gives a misleading result.

Labelling and returning the sample

Before returning the bottles, make sure each one is clearly labelled with your full name, date of birth, and hospital number, plus the collection start and end date and time. Mislabelled or unlabelled samples will be rejected by the laboratory.

Return the bottles the same day you finish the collection, together with the request form. If your collection is for creatinine clearance, you will also need a blood test for creatinine on the same day — book this in advance.

Tacrolimus is an immunosuppressant medicine used to treat certain types of kidney inflammation (glomerulonephritis), including minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis (FSGS), and Class V lupus nephritis. It works by calming the immune system to reduce inflammation and protein leakage into the urine.

Off-license use

Tacrolimus is not formally licensed in the UK for glomerulonephritis, but it is widely used by kidney specialists based on substantial clinical experience and medical evidence. "Off-license" simply means it is prescribed outside its original approval — this is common in nephrology and does not mean it is experimental or unsafe.

How to take it

  • Always use the same brand — Adoport
  • Take it at 10am and 10pm, one hour before or two hours after food
  • Take it every day without skipping doses

What to avoid

  • Grapefruit and grapefruit juice (affects drug levels)
  • St John's Wort and other herbal remedies
  • Anti-inflammatory painkillers such as ibuprofen
  • Some antibiotics (e.g. clarithromycin) and antifungal or epilepsy medicines
  • Always check with Dr Lawrence or your pharmacist before starting any new medicine

Blood level monitoring

Regular blood tests are essential to keep tacrolimus at the right level — too low and it will not work; too high and it may affect kidney function. The typical schedule is:

  • After approximately 5 doses (first check)
  • Weekly until levels are stable
  • Monthly once established
  • Every 2 months for long-term treatment

The target blood level is 5–8 ng/mL, adjusted based on your response.

How long will treatment last?

Most patients take tacrolimus for around two years, though this varies. The dose is gradually reduced depending on response. Treatment is considered successful if:

  • Partial remission: urine protein falls by more than 50%
  • Complete remission: urine protein-to-creatinine ratio (uPCR) falls below 50

If there is no meaningful improvement after 3–6 months, treatment will be stopped.

Side effects to be aware of

Common or important side effects include tremor, headache, sleep disturbance, raised blood sugar, high potassium, high blood pressure, hair thinning, and increased susceptibility to infection. There is also a small long-term increase in risk of certain cancers, particularly skin cancer and lymphoma — sun protection is important.

Seek urgent medical attention if you develop: severe headache, confusion or seizures, sudden worsening of kidney function, or extreme tiredness or muscle weakness.

Pregnancy and fertility

Tacrolimus is considered safe in pregnancy and during breastfeeding. Contraception is recommended while being actively treated for kidney disease. Please let Dr Lawrence know if you are planning a pregnancy or are breastfeeding.

Don't Panic! — book cover
Published by Ariadne's Thread

Don't Panic!

Dr Christopher Lawrence — BSc · MBBS · LLM · MD · FRCP

A Kidney Doctor's Straight-Talking Guide to Chronic Kidney Disease (CKD). Written from the perspective of the consulting room — the questions patients actually ask, answered clearly and without jargon.

Whether you have just been told your eGFR is low, are living with established CKD, or are supporting someone after a kidney transplant, this book gives you the knowledge to understand what is happening, ask better questions, and face your diagnosis with confidence rather than fear.

"No one has ever explained it to me like that before." — patient review

Coming soon on Amazon
Patient Feedback

What patients say

★★★★★

"My father has been seen by Dr Christopher, and I'm here to express my total appreciation regarding this consultation. It was extraordinary — I am very pleased that the universe made me call this extraordinary doctor when I was researching for a kidney specialist."

2025 · via Doctify
★★★★★

"I cannot praise Dr Lawrence too highly. He saw me within 24 hours of making an appointment. Carefully listened to what I had to say, gave me a thorough physical examination, analysed a specimen and provided an interim solution which kept me out of hospital."

2025 · via Doctify
★★★★★

"Dr Lawrence has been monitoring my husband's condition daily. The type of input from a doctor is in my experience extremely rare — but Dr Lawrence makes the time to ensure my husband feels supported and listened to. His extensive knowledge and personally engaging manner means he's easy to talk to."

2025 · via Doctify
★★★★★

"I don't recall seeing another doctor who has been so willing and able to explain symptoms, diagnosis and planned treatment in a way in which the patient can understand."

2025 · via Doctify
Read all reviews on Doctify Doctify Great Patient Experience 2026
Research & Academic Work

Publications

Dr Lawrence has presented research at national and international conferences including the American Society of Nephrology and the American Transplant Congress, and co-supervised PhD research at the University of Hertfordshire.

Transplant
Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study High Impact
Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, Billings P, Lawrence C, Lowe D, Hidalgo LG; the Trifecta Investigators.
Transplantation · 2023 · 107(3):709–719 · PMID 36190186
Key Finding

In transplant patients with antibody-mediated rejection (AMR), elevated donor-derived cell-free DNA (dd-cfDNA) was detected in the blood even when conventional donor-specific antibody (DSA) testing was negative. This establishes cfDNA as an independent biomarker of rejection — capable of detecting graft injury that serological testing alone would miss.

Response to Commentary on development of the molecular microscope (MMDx) assay for heart transplant rejection surveillance
Manion H, McCloskey C, Ramesh P, Lawrence C.
Cardiovascular Pathology · 2023 · 63:107486 · PMID 36202192
The Molecular Microscope Diagnostic System (MMDx) interpretation of solid organ allograft biopsies: Restoring the perspective
McCloskey C, Zubrycki M, Lawrence C.
Clinical Transplantation · 2022 · 36(8):e14711 · PMID 35668041
US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies
Fusfeld L, Menon S, Gupta G, Lawrence C, Masud SF, Goss TF.
Journal of Medical Economics · 2022 · 25(1):515–523 · PMID 35345966
Transplant programs during COVID-19: Unintended consequences for health inequality
Sharma S, Lawrence C, Giovinazzo F.
American Journal of Transplantation · 2020 · 20(7):1954–1955 · PMID 32314551
Adherence Behavior in Subjects on Hemodialysis Is Not a Clear Predictor of Posttransplantation Adherence High Impact
Hucker A, Lawrence C, Sharma S, Farrington K.
Kidney International Reports · 2019 · 4(8):1122–1130 · PMID 31440702
Key Finding

Pre-transplant adherence behaviour during haemodialysis does not reliably predict whether a patient will adhere to immunosuppression after transplantation. This challenges the common clinical assumption that dialysis adherence can be used as a proxy marker when selecting transplant candidates.

Non-adherence to immunosuppressants following renal transplantation: a protocol for a systematic review
Hucker A, Bunn F, Carpenter L, Lawrence C, Farrington K, Sharma S.
BMJ Open · 2017 · 7(9):e015411 · PMID 28963283
Complement-binding anti-HLA antibodies and kidney transplantation N Engl J Med
Lawrence C, Clarke C, Willicombe M.
New England Journal of Medicine · 2014 · 370(1):84–85 · PMID 24382078
Key Finding

Published in the New England Journal of Medicine, this correspondence contributed to establishing the clinical significance of complement-binding (C1q-fixing) anti-HLA donor-specific antibodies in kidney transplantation — a functionally distinct subclass of DSA associated with significantly worse transplant outcomes and antibody-mediated rejection.

Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts High Impact
Lawrence C, Willicombe M, Brookes PA, Santos-Nunez E, Bajaj R, Cook T, Roufosse C, Taube D, Warrens AN.
Transplantation · 2013 · 95(2):341–346 · PMID 23197178
Key Finding

Even low-level pre-existing donor-specific antibodies can accurately predict early antibody-mediated rejection — but only when those antibodies are capable of activating complement. The functional quality of DSA (its ability to fix complement) matters as much as its quantity, with important implications for pre-transplant risk stratification and immunological workup.

Exploring the views of patients not on the transplant waiting list: a qualitative study
Lawrence C, Sharma S, Da Silva-Gane M, Fletcher BC, Farrington K.
Journal of Renal Care · 2013 · 39(2):118–124 · PMID 23683305
Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic?
Lawrence C, Galliford JW, Willicombe MK, McLean AG, Lesabe M, Rowan F, Papalois V, Regan F, Taube D.
Transplantation · 2011 · 92(10):1129–1133 · PMID 21959216
Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil
Borrows R, Chan K, Loucaidou M, Lawrence C, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D.
Transplantation · 2006 · 81(1):125–128 · PMID 16421488
Nephrology & Dialysis
Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease RCT · High Impact
Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, Pattison J, Bhandari S, Barratt J, Turner N, Cook HT, Levy JB, Lightstone L, Pusey C, Galliford J, Cairns TD, Griffith M.
Clinical Journal of the American Society of Nephrology · 2020 · 15(2):209–218 · PMID 31953303
Key Finding

In this multicentre randomised controlled trial — the first of its kind in de novo minimal change disease — tacrolimus monotherapy achieved remission rates equivalent to prednisolone monotherapy, while avoiding the significant metabolic and systemic side effects associated with long-term steroid use. This supports tacrolimus as a first-line alternative in patients for whom steroids are poorly tolerated or contraindicated.

Seasonal relapsing minimal change disease: a novel strategy for avoiding long-term immunosuppression
Lawrence C, Cook HT, Lightstone L.
Case Reports in Nephrology and Urology · 2012 · 2(2):102–107 · PMID 23197964
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
Jolly EC, Clatworthy MR, Lawrence C, Nathan PD, Farrington K.
NDT Plus · 2009 · 2(4):300–302 · PMID 25984021
Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity High Impact
Chandna SM, Schulz J, Lawrence C, Greenwood RN, Farrington K.
BMJ · 1999 · 318(7178):217–223 · PMID 9915728
Key Finding

Published in the BMJ, this landmark cohort study examined which factors predict survival and morbidity in patients on chronic dialysis. The findings provided an evidence base for clinical decision-making around dialysis initiation, contributing to the ethical and practical framework for rationing decisions — a question that remains clinically and politically important today.

General Medicine
A rare cause of abdominal pain, diarrhoea and GI bleeding: Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV)
Laskaratos FM, Hamilton M, Novelli M, Shepherd N, Jones G, Lawrence C, Mitchison M, Murray CD.
Gut · 2015 · 64(2):214, 350 · PMID 25342827
Progressive periodic hypothermia and bradycardia
Dubrey SW, Rosser G, Shah KP, Lawrence C, Baburaj R, Mitchell C.
British Journal of Hospital Medicine · 2013 · 74(5):292–293 · PMID 23657028
Coronary vasomotor and cardiac electrophysiologic effects of diadenosine polyphosphates and nonhydrolyzable analogs in the guinea pig
Stavrou BM, Lawrence C, Blackburn GM, Cohen T, Sheridan DJ, Flores NA.
Journal of Cardiovascular Pharmacology · 2001 · 37(5):571–584 · PMID 11336108
Clinics

Where to find us

London

9 Harley Street

9 Harley Street
London
W1G 9QY
020 7079 2100
Hertfordshire

One Hatfield Hospital

Hatfield Business Park
Hatfield
AL10 9UA
01707 443333
Hertfordshire

Spire Bushey Hospital

Heathbourne Road
Bushey
WD23 1RD
0208 950 9090
Cambridgeshire

Spire Cambridge Lea

30 New Road
Impington, Cambridge
CB24 9EL
01223 266900
Secretary — Elaine Coles
For appointment enquiries: 07375 064324  ·  info@hertskidneycare.co.uk

Ready to make an appointment?

Book online via Doctify, or contact the secretary directly.

Book via Doctify Email the secretary